An inflammatory cytokine signature predicts COVID-19 severity and survival

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

(2020) Qiurong Ruan et al.   INTENSIVE CARE MEDICINE

Myeloma CAR-T CRS Management with IL-1R Antagonist Anakinra

(2020) Shashidhar S. Jatiani et al.   Clinical Lymphoma Myeloma & Leukemia

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

(2020) Safiya Richardson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed

(2020) Marc Feldmann et al.   LANCET

COVID-19: consider cytokine storm syndromes and immunosuppression

(2020) Puja Mehta et al.   LANCET

Viral and host factors related to the clinical outcome of COVID-19

(2020) Xiaonan Zhang et al.   NATURE

Effective treatment of severe COVID-19 patients with tocilizumab

(2020) Xiaoling Xu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cytokine release syndrome in severe COVID-19

(2020) John B. Moore et al.   SCIENCE

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China

(2020) Chaomin Wu et al.   JAMA Internal Medicine

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

(2020) Jing Liu et al.   EBioMedicine

A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward

(2020) Bo Wang et al.   Journal of Hematology & Oncology

Coronavirus breakthrough: dexamethasone is first drug shown to save lives

(2020) Heidi Ledford   NATURE

Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report

(2020)   NEW ENGLAND JOURNAL OF MEDICINE

SOHO State of the Art Updates and Next Questions: T-Cell–Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor–Modified T Cells and Bispecific T-Cell–Engaging Agents

(2019) Deepu Madduri et al.   Clinical Lymphoma Myeloma & Leukemia

Subdistribution hazard models for competing risks in discrete time

(2018) Moritz Berger et al.   BIOSTATISTICS

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents

(2014) John C Rohloff et al.   Molecular Therapy-Nucleic Acids

External validation of a Cox prognostic model: principles and methods

(2013) Patrick Royston et al.   BMC Medical Research Methodology

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

(2012) Charles A. Dinarello et al.   NATURE REVIEWS DRUG DISCOVERY

A practical guide to understanding Kaplan-Meier curves

(2010) Jason T. Rich et al.   OTOLARYNGOLOGY-HEAD AND NECK SURGERY

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

(2008) N. Nishimoto et al.   BLOOD